Companion Diagnostics and Emerging Biomarkers: A Year-End Review
This session will discuss how FDA-approved companion diagnostics and laboratory-developed tests all impact the way patients receive treatment and therapy. How was the need for new diagnostic tests in 2022 to support precision medicine addressed by your lab?
DXRX provides insights to registered labs to facilitate their planning for new testing and test indications.
Date and time: Wednesday November 16th, 2022 12pm (ET)
Speaker name: Dr. Anthony Magliocco, MD
Agenda:
• Welcome & introduction to DXRX [5mins]
• Companion Diagnostics and Emerging Biomarkers: A Year-End Review [45mins]
• Discussion and Q&A [10 mins]
A recording of this session will be made available on DXRX post event
This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology (ASCP) as meeting the criteria for 1.0 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program.
Speaker name: Dr. Anthony Magliocco, MD
Dr. Magliocco has over 30 years of experience in tissue pathology, research, molecular diagnostics, and digital image analysis. He has founded and led multiple laboratories and has overseen the deployment of numerous new laboratory tests in his career in both Canada and the USA. He has published over 200 research articles, has numerous patents applied, and is a frequent invited speaker to international diagnostic technology meetings. In his research he has developed new digital image analysis methods and has created numerous new diagnostic tests for use in better selecting treatment plans for patients with breast, ovary, lung, bladder, and many other cancers.